Iqvia – Solutions Segment Breakdown & H1 2023 Growth Trajectory

  • Public Equity
  • Healthcare
  • North America


Former VP at Iqvia Holdings Inc


  • Developments in pharmaceutical and support services environment, discussing high demand for multi-service and bundled offerings
  • Service expansion opportunities and product analysis – DCTs (decentralised clinical trials), FSP (functional service provider) sourcing, technological capabilities and quality and safety checks
  • Iqvia’s (NYSE: IQV) consolidation efforts to digitise drug development, discussing potential acquisition targets
  • Competitive positioning in relation to key competitors, including Icon (NASDAQ: ICLR)-PRA and Veeva (NYSE: VEEV)
  • Near-term outlook for Iqvia, including projected Q4 2022 financial performance


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited